Parkinson Disease, Secondary
"Parkinson Disease, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Descriptor ID |
D010302
|
| MeSH Number(s) |
C10.228.140.079.862.800 C10.228.662.600.700
|
| Concept/Terms |
Parkinson Disease, Secondary- Parkinson Disease, Secondary
- Secondary Parkinson Disease
- Symptomatic Parkinson Disease
- Parkinsonism, Symptomatic
- Symptomatic Parkinsonism
- Secondary Parkinsonism
- Parkinson Disease, Symptomatic
- Parkinsonism, Secondary
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease, Secondary".
This graph shows the total number of publications written about "Parkinson Disease, Secondary" by people in this website by year, and whether "Parkinson Disease, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease, Secondary" by people in Profiles.
-
Patel P, Pol A, Kalaria D, Date AA, Kalia Y, Patravale V. Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. Eur J Pharm Biopharm. 2021 Aug; 165:66-74.
-
Martin CA, Barajas A, Lawless G, Lawal HO, Assani K, Lumintang YP, Nunez V, Krantz DE. Synergistic effects on dopamine cell death in a Drosophila model of chronic toxin exposure. Neurotoxicology. 2014 Sep; 44:344-51.
-
Ferguson MC, Nayyar T, Ansah TA. Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease. Neurochem Int. 2014 May; 71:36-46.
-
Racette BA, Aschner M, Guilarte TR, Dydak U, Criswell SR, Zheng W. Pathophysiology of manganese-associated neurotoxicity. Neurotoxicology. 2012 Aug; 33(4):881-6.
-
King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011 Oct 24; 89(17-18):638-43.
-
Lamango NS, Charlton CG. Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol Biochem Behav. 2000 Aug; 66(4):841-9.
-
Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci N. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psychiatry. 1996 Feb; 60(2):213-6.
-
Charlton CG, Crowell B. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav. 1992 Oct; 43(2):423-31.
-
Galloway PG, Bergeron C, Perry G. The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. Neurosci Lett. 1989 May 22; 100(1-3):6-10.
-
Garruto RM, Yanagihara R, Gajdusek DC. Cycads and amyotrophic lateral sclerosis/parkinsonism dementia. Lancet. 1988 Nov 05; 2(8619):1079.